Why Is Coherus BioSciences Stock Trading Higher On Tuesday?
Why Is Coherus BioSciences Stock Trading Higher On Tuesday?
"The proposed divestiture of Udenyca represents the successful execution of our strategy to focus R&D and commercial resources on Coherus' innovative immuno-oncology portfolio and to strengthen our financial position," said On Tuesday, Coherus BioSciences, Inc. (NASDAQ:CHRS) entered into an asset purchase agreement with Intas Pharmaceuticals Ltd for the divestiture of the Udenyca (pegfilgrastim-cbqv) franchise for up to $558.4 million.
在週二，coherus biosciences, inc.（納斯達克：CHRS）與Intas Pharmaceuticals Ltd達成了一項資產購買協議，出售Udenyca（pegfilgrastim-cbqv）業務，金額高達55840萬。
The deal consideration includes an upfront payment of $483.4 million, to be adjusted for inventory at the close, and $75 million in potential net sales milestone payments.
該交易的對價包括48340萬的預付款，交易結束時將根據庫存進行調整，以及7500萬的潛在淨銷售里程碑付款。
Coherus plans to use a portion of the transaction proceeds to fully repay the company's $230 million in existing convertible notes due April 2026 and $49.1 million to buy out certain royalty obligations related to Udenyca.
Coherus計劃將交易收益的一部分用於全額償還公司23000萬的現有可轉換債券（到期日爲2026年4月）和4910萬用於買斷與Udenyca相關的某些特許權使用費義務。
"The proposed divestiture of Udenyca represents the successful execution of our strategy to focus R&D and commercial resources on Coherus' innovative immuno-oncology portfolio and to strengthen our financial position," said Denny Lanfear, Coherus chairman and chief executive officer.
coherus董事長兼首席執行官Denny Lanfear表示：「擬議的Udenyca出售代表了我們成功實施戰略的結果，旨在將研發和商業資源聚焦於coherus的創新免疫腫瘤組合，並增強我們的財務狀況。」
The proposed transaction is expected to close by the end of Q1 2025.
預計交易將在2025年第一季度末完成。
Coherus intends to strengthen and sharpen its focus on advancing its immuno-oncology portfolio in combination with Loqtorzi, a next-generation, differentiated PD-1 marketed in the U.S. in two indications.
Coherus打算加強並明確關注推進其免疫腫瘤組合，與Loqtorzi聯合，這是一種在美國上市的下一代、差異化的PD-1，有兩個適應症。
Additional partnerships evaluating Loqtorzi with other cancer agents are planned for 2025.
計劃在2025年與其他癌症藥物共同評估Loqtorzi的額外合作伙伴關係。
The company plans to initiate a Phase 2 trial of casdozokitug/toripalimab/bevacizumab in first-line (1L) hepatocellular carcinoma (HCC) in Q4 2024, with final data from Phase 2 trial of casdozokitug/atezolizumab/bevacizumab in 1L HCC in Q1 2025, and data from its Phase 1 study of casdozokitug/toripalimab in second to fourth line (2-4L) non-small cell lung cancer (NSCLC) in 1H 2025.
該公司計劃在2024年第四季度啓動casdozokitug/toripalimab/bevacizumab在一線（1L）肝細胞癌（HCC）中的第二階段試驗，在2025年第一季度獲得casdozokitug/atezolizumab/bevacizumab在1L HCC的第二階段試驗的最終數據，以及在2025年上半年獲得casdozokitug/toripalimab在第二到第四線（2-4L）非小細胞肺癌（NSCLC）中的第一階段研究數據。
Coherus plans to:
Coherus計劃：
- Report Phase 1 monotherapy biopsy data and CHS-114/toripalimab combination safety data in head and neck squamous cell carcinoma (HNSCC) in 1H 2025.
- Initiate a Phase 1b CHS-114/toripalimab combination dose optimization study in 2L head and neck squamous cell carcinoma in Q1 2025, with a first data readout expected in Q2 2026.
- Initiate a Phase 1b CHS-114/toripalimab combination dose optimization study in 2L gastric cancer in Q1 2025, with a first data readout expected in Q2 2026.
- 在2025年上半年報告單藥生物活檢數據以及CHS-114/託瑞帕利組合在頭頸部鱗狀細胞癌（HNSCC）中的安全性數據。
- 在2025年第一季度啓動一項針對2L頭頸部鱗狀細胞癌的10億CHS-114/託瑞帕利組合劑量優化研究，預計在2026年第二季度進行首次數據讀取。
- 在2025年第一季度啓動一項針對2L胃癌的10億CHS-114/託瑞帕利組合劑量優化研究，預計在2026年第二季度進行首次數據讀取。
Earlier this year, Coherus BioSciences divested its Cimerli ophthalmology franchise to Sandoz Group AG (OTC:SDZNY) (OTC:SDZXF) for $170 million plus an additional amount for inventory.
今年早些時候，Coherus Biosciences將其Cimerli眼科醫療業務出售給Sandoz Group AG（場外交易:SDZNY）（場外交易:SDZXF），交易金額爲17000萬美元，加上額外的庫存金額。
Price Action: CHRS stock is up 41.6% at $1.94 at last check Tuesday.
價格動態：截至週二最後檢查，CHRS股票上漲41.6%，報1.94美元。
- Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline
- Merus獲得癌症潛在藥物Zenocutuzumab的美國商業化權利，分析師強調Merus的產品線
Photo: Shutterstock
Photo: shutterstock
